The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
Willingness to provide written informed consent for the study.
Male or female subjects, age 18-45 years older.
Within body mass index (BMI) range 19.0 to 26.0 kilograms per square meter (kg/m²).
The results of vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray and other examinations during the screening period are normal or judged to be abnormal by the investigator and have no clinical significance.
History of severe allergies or allergies to 611 and any of its components;
Previous or current disease that may affect the safety of the subject's participation in the trial or the in vivo process of the trial drug;
Any history of VKC and AKC;
History of drug abuse within 2 years prior to screening;
Parallel
new formulations of 611
DrugSubjects will receive new formulations of 611 300mg once subcutaneous injection on D1
existing formulations of 611
DrugSubjects will receive existing formulations of 611 300mg once subcutaneous injection on D1
Cmax
AUC
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
